REDOXTHERAPIES

RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. Redox has compiled key assets in this space, including an exclusive license to vipadenant, a potent and selective A2a adenosine receptor antagonist, and intellectual property covering the combination of adenosine antagonists with immuno-modulatory agents.